Gennatas Constantine, Michalaki Vasiliki, Gennatas Spyridon
Areteion Hospital, Oncology Clinic, Department of Surgery, Athens, Greece.
Rev Recent Clin Trials. 2009 Jan;4(1):1-11. doi: 10.2174/157488709787047576.
Capecitabine has been developed as a prodrug of FU, with the goal of improving tolerability and intratumor drug concentration through tumor-specific conversion to the active drug. The purpose of this article is to review the available information on capecitabine with respect to clinical efficacy for tumors of the digestive tract, adverse-effect profile, documented drug interactions, dosage and administration, and future directions of ongoing research. Relevant English-language literature was identified through searches of NCI, PubMed, ASCO.org and ESMO, ECCO meetings proceedings.
卡培他滨是作为氟尿嘧啶的前体药物开发的，目的是通过肿瘤特异性转化为活性药物来提高耐受性和肿瘤内药物浓度。本文的目的是综述关于卡培他滨在消化道肿瘤临床疗效、不良反应谱、已记录的药物相互作用、剂量和给药方法以及正在进行的研究的未来方向等方面的现有信息。通过检索美国国立癌症研究所（NCI）、PubMed、美国临床肿瘤学会（ASCO.org）以及欧洲肿瘤内科学会（ESMO）、欧洲癌症研究与治疗组织（ECCO）会议论文集来确定相关的英文文献。
